YD Bio Limited Ordinary Shares Return on Equity

YD Bio Limited Ordinary Shares (YDES) currently reports a ROE of 104.17%. That is above the Healthcare sector average of 21.67%. Use the charts on this page to explore YD Bio Limited Ordinary Shares's ROE history and peer comparisons.

YD Bio Limited Ordinary Shares's ROE of 104.17% is higher than the Healthcare sector average of 21.67%. That is roughly 380.7% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but YD Bio Limited Ordinary Shares's current 104.17% should be judged against Healthcare norms (sector average: 21.67%) and against YDES's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 104.17%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.67%. From there, open related valuation or income-statement pages for YD Bio Limited Ordinary Shares, and consider following YDES for alerts when major investors trade the stock.

YD Bio Limited Ordinary Shares is classified in the Healthcare sector. On ROE, it currently shows 104.17% versus a sector average near 21.67%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing YDES with unrelated industries.